Jeonjin Biopharm, 1.8 Billion KRW Paid-in Capital Increase Targeting Yuhan Corporation

[Asia Economy Reporter Jang Hyowon] Jeonjin Bio Pharm announced on the 30th that it has decided on a third-party allotment paid-in capital increase worth 1.8 billion KRW targeting Yuhan Corporation.

Of the raised funds, 1 billion KRW will be used for facility investment, and 800 million KRW will be used for operating expenses. The issue price per new share is 3,605 KRW.